CD8A and ovarian neoplasm: This complexity ties into broader immunotherapeutic strategies, such as HLA ligandomics, where HDAC1-derived peptides identified on ovarian tumor samples stimulate multifunctional CD8 + T-cell responses in vitro, despite their absence among TILs in vivo, possibly due to immune escape or thymic tolerance.